دورية أكاديمية
أعرض في EDS

Safety and Immunogenicity of an In Vivo Muscle Electroporation Delivery System for DNA- hsp65 Tuberculosis Vaccine in Cynomolgus Monkeys.

التفاصيل البيبلوغرافية
العنوان: Safety and Immunogenicity of an In Vivo Muscle Electroporation Delivery System for DNA- hsp65 Tuberculosis Vaccine in Cynomolgus Monkeys.
المؤلفون: de Lima MR; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Leandro ACCS; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil.; Division of Human Genetics, South Texas Diabetes and Obesity Institute, The University of Texas Rio Grande Valley, Brownsville, TX 78520, USA., de Souza AL; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Barradas MM; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Roma EH; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Fernandes ATG; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Galdino-Silva G; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Carvalho JKMR; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Marchevsky RS; Laboratory of Neurovirulence, Instituto de Biotecnologia em Imunobiológicos, Biomanguinhos, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Coelho JMCO; Laboratory of Pathology, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil., Gonçalves EDC; Farmacore Biotecnologia Ltda, Ribeirão Preto 14056-680, SP, Brazil., VandeBerg JL; Division of Human Genetics, South Texas Diabetes and Obesity Institute, The University of Texas Rio Grande Valley, Brownsville, TX 78520, USA., Silva CL; Farmacore Biotecnologia Ltda, Ribeirão Preto 14056-680, SP, Brazil.; Laboratory for Research and Development of Immunobiologicals, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil., Bonecini-Almeida MDG; Laboratory of Immunology and Immunogenetic in Infectious Diseases, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, RJ, Brazil.
المصدر: Vaccines [Vaccines (Basel)] 2023 Dec 18; Vol. 11 (12). Date of Electronic Publication: 2023 Dec 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: A Bacille Calmette-Guérin (BCG) is still the only licensed vaccine for the prevention of tuberculosis, providing limited protection against Mycobacterium tuberculosis infection in adulthood. New advances in the delivery of DNA vaccines by electroporation have been made in the past decade. We evaluated the safety and immunogenicity of the DNA-hsp65 vaccine administered by intramuscular electroporation (EP) in cynomolgus macaques. Animals received three doses of DNA-hsp65 at 30-day intervals. We demonstrated that intramuscular electroporated DNA-hsp65 vaccine immunization of cynomolgus macaques was safe, and there were no vaccine-related effects on hematological, renal, or hepatic profiles, compared to the pre-vaccination parameters. No tuberculin skin test conversion nor lung X-ray alteration was identified. Further, low and transient peripheral cellular immune response and cytokine expression were observed, primarily after the third dose of the DNA-hsp65 vaccine. Electroporated DNA-hsp65 vaccination is safe but provides limited enhancement of peripheral cellular immune responses. Preclinical vaccine trials with DNA-hsp65 delivered via EP may include a combination of plasmid cytokine adjuvant and/or protein prime-boost regimen, to help the induction of a stronger cellular immune response.
References: Immunology. 1999 Aug;97(4):573-81. (PMID: 10457209)
Mol Med Rep. 2015 Aug;12(2):3073-80. (PMID: 25962477)
Cell Rep Med. 2021 Aug 17;2(8):100372. (PMID: 34467249)
Vaccines (Basel). 2020 Dec 07;8(4):. (PMID: 33297341)
Immunity. 2011 May 27;34(5):807-19. (PMID: 21596592)
Front Med Technol. 2020 Dec 15;2:603690. (PMID: 35047886)
PLoS One. 2020 May 29;15(5):e0233151. (PMID: 32469893)
J Immunol Methods. 2004 May;288(1-2):61-79. (PMID: 15183086)
PLoS One. 2022 May 26;17(5):e0269109. (PMID: 35617254)
Hum Vaccin Immunother. 2015;11(8):1991-2004. (PMID: 25996997)
Iran J Microbiol. 2016 Apr;8(2):132-8. (PMID: 27307979)
Vaccine. 2009 Jul 23;27(34):4709-17. (PMID: 19500524)
J Infect Dis. 2019 Jan 29;219(4):544-555. (PMID: 30304515)
PLoS One. 2014 Oct 22;9(10):e111085. (PMID: 25338098)
Front Immunol. 2022 May 04;13:876579. (PMID: 35603155)
Medicine (Baltimore). 2018 Nov;97(45):e13120. (PMID: 30407329)
Clin Chest Med. 2019 Dec;40(4):703-719. (PMID: 31731979)
Vaccine. 2017 Dec 15;35(50):7049-7056. (PMID: 29132995)
Curr Opin Immunol. 2011 Jun;23(3):421-9. (PMID: 21530212)
Hum Vaccin Immunother. 2017 Dec 2;13(12):2902-2911. (PMID: 29045192)
Tuberculosis (Edinb). 2018 Dec;113:65-75. (PMID: 30514515)
J Infect Dis. 2013 Sep 1;208(5):818-29. (PMID: 23840043)
Hum Vaccin Immunother. 2017 May 4;13(5):1040-1050. (PMID: 28059670)
J Antimicrob Chemother. 2015;70(6):1774-83. (PMID: 25687643)
Vaccine. 2008 Aug 18;26(35):4536-40. (PMID: 18602439)
PLoS One. 2012;7(1):e29231. (PMID: 22242162)
Cell Rep. 2017 Mar 28;18(13):3091-3104. (PMID: 28355562)
Nat Microbiol. 2021 Feb;6(2):187-195. (PMID: 33257849)
J Immunol. 2014 Dec 15;193(12):5765-71. (PMID: 25480955)
Clin Vaccine Immunol. 2011 May;18(5):707-16. (PMID: 21450977)
Cell Rep Med. 2021 Oct 19;2(10):100420. (PMID: 34604818)
Nat Commun. 2015 Oct 13;6:8533. (PMID: 26460802)
Scand J Immunol. 2014 May;79(5):292-8. (PMID: 24498941)
Hum Vaccin Immunother. 2013 Oct;9(10):2246-52. (PMID: 24051434)
Clin Exp Vaccine Res. 2015 Jan;4(1):83-7. (PMID: 25649326)
PLoS One. 2018 Sep 20;13(9):e0202753. (PMID: 30235286)
Gene Ther. 2005 Feb;12(3):281-7. (PMID: 15526006)
Genet Vaccines Ther. 2008 Jan 21;6:3. (PMID: 18208592)
Vaccine. 2017 Apr 11;35(16):2042-2051. (PMID: 28318765)
Vaccine. 2004 Jun 23;22(19):2489-93. (PMID: 15193413)
Vaccines (Basel). 2016 Sep 12;4(3):. (PMID: 27626449)
Rep Biochem Mol Biol. 2016 Apr;4(2):89-97. (PMID: 27536702)
Vaccine. 2006 May 22;24(21):4565-8. (PMID: 16154246)
BMC Immunol. 2017 Feb 27;18(1):11. (PMID: 28241799)
Hum Vaccin Immunother. 2014;10(8):2188-98. (PMID: 25424922)
Biochem Biophys Res Commun. 2008 Feb 1;366(1):29-35. (PMID: 18036339)
Vaccine. 2016 Nov 4;34(46):5571-5578. (PMID: 27697302)
Science. 1939 May 12;89(2315):442-3. (PMID: 17816952)
Lancet Microbe. 2022 Mar;3(3):e173-e183. (PMID: 35156068)
Vaccine. 2019 Jul 26;37(32):4444-4453. (PMID: 31279565)
J Gene Med. 2009 Jan;11(1):66-78. (PMID: 19035575)
Immunology. 2004 Sep;113(1):130-8. (PMID: 15312144)
Immunology. 2012 Nov;137(3):239-48. (PMID: 22891805)
Front Immunol. 2022 Feb 24;13:827605. (PMID: 35281016)
Hum Gene Ther. 2009 Nov;20(11):1291-307. (PMID: 19627235)
Genet Vaccines Ther. 2007 Aug 22;5:7. (PMID: 17714584)
PLoS One. 2015 Jul 14;10(7):e0132288. (PMID: 26172261)
World J Gastroenterol. 2017 Jan 14;23(2):306-317. (PMID: 28127204)
Nat Rev Immunol. 2002 Mar;2(3):185-94. (PMID: 11913069)
معلومات مُعتمدة: R01 AI065697 United States AI NIAID NIH HHS; R01 AI065697 United States NH NIH HHS
فهرسة مساهمة: Keywords: DNA-hsp65; electroporation; immunogenicity; nonhuman primate; safety; tuberculosis; vaccine
تواريخ الأحداث: Date Created: 20231223 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10747856
DOI: 10.3390/vaccines11121863
PMID: 38140266
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines11121863